FOIAengine: Hundreds of Requests Targeted Biden Connections at Center for American Progress Months before Donald Trump threatened the Center for American Progress, the influential progressive policy organization, with a $5 billion defamation lawsuit,...
FDA’s Peptide Push Draws Questions
FOIAengine: Newly Remade Advisory Committee Green Lights Six Compounds, Despite the Applications Being Pulled Bobby Harshbarger is a Tennessee state senator and pharmacist of noteworthy lineage, with an interesting backstory. Both of his parents are...
How Reporters Used FOIA to Cover Cyclospora Outbreak
FOIAengine: Twenty-One Requests from News Media, Non-Profits and Companies The nationwide outbreak of cyclospora infections this summer prompted a steady stream of national and local news articles, along with 21 Freedom of Information Act requests to the Food and Drug...
Hard Questions for SEC about Google, Meta
As the artificial-intelligence arms race heats up, Meta and Google have turned to Wall Street for help paying the multi-billion-dollar tab. Amid data-center financing terms that even Google’s auditor calls questionable, a Washington securities lawyer whose clients...
How Hedge Funds Use FOIA to Track FDA’s Regulatory Aftermath
FOIAengine: Requests from Point72, Sofinnova, Holocene, Triple Gate and Others A review of the latest Freedom of Information Act requests targeting three life-sciences companies – Novo Nordisk (NYSE: NVO); Charles River Laboratories (NYSE: CRL); and iRhythm...
How Media Requesters Used FOIA to Probe Trump GLP-1 Mystery
FOIAengine: Multiple News Outlets Sought Details on “Compassionate Use” Within days of a Stat News report describing a highly unusual government decision to grant a 79-year-old patient early access to Eli Lilly’s experimental obesity drug retatrutide, some of the...





